EP 212: A hub-and-spoke model for accelerating rare disease drug development with Ananth Sridhar ...

Value of the Information & Strength of the Argument

The podcast provides valuable insights into the hub-and-spoke model, explaining both operational and financial benefits. The guests argue convincingly that this model allows for risk diversification and enables development of drugs for rare diseases that might otherwise be neglected. They support their points with specific examples, such as the ADH1 program, and reference a peer-reviewed publication. The argumentation is solid, grounded in their professional experience and data from genetic studies.

Scientific Rigor, Source Quality, Title Accuracy

The guests demonstrate scientific rigor by referencing a peer-reviewed publication in the American Journal of Human Genetics and discussing quantitative approaches like risk-adjusted NPV. They also mention collaborations with academic scientists. The title accurately reflects the content, focusing on the hub-and-spoke model and rare disease drug development. The podcast is an expert opinion piece, and while not a formal scientific review, it provides credible insights from industry leaders.

The title accurately reflects the main topic: the hub-and-spoke model for rare disease drug development, with a focus on BridgeBio's approach.

8/10

The podcast features two senior executives from BridgeBio with extensive experience in drug development and computational genomics. They discuss specific programs and cite a peer-reviewed publication. The content is expert opinion, but grounded in their professional experience and some published data.

• 00:00Intro to The Genetics Podcast
• 00:59Welcome to Ananth & Sun-Gou
• 01:57How BridgeBio’s hub-and-spoke model de-risks and accelerates rare disease drug development
• 06:45How programs move from the hub to the spokes in target discovery and development
• 09:10Translating a target into a therapy for autosomal dominant hypocalcemia type 1 (ADH1)
• 12:28Challenges in ADH1 drug development and using population genetics to identify patients with gain-of-function variants
• 18:08Under-diagnosis and incomplete penetrance in rare disease and quantifying genetic versus phenotypic prevalence
• 20:52Balancing first-in-class innovation with risk management in rare disease drug development
• 24:24Evaluating rare disease programs using risk-adjusted net present value (NPV) instead of peak sales
• 27:20Key factors that can make rare disease programs faster and cheaper to develop, and why modality agnosticism is important
• 32:00Sun-Gou’s experience in computational genetics and building data-driven infrastructure for discovery
• 36:44Ananth’s lessons from Regeneron and applying patient-centered principles to rare disease drug development
• 39:00Sun-Gou on the power of newborn sequencing and personal lessons from early diagnosis
• 43:36Ananth’s views on making predictive medicine more personal and human-centered
• 44:51Closing remarks

• BridgeBio - Unlocking Rare Diseases Medicine — Mentioned as a resource for more information about BridgeBio's work.
• Hub-and-spoke model video — Referenced as a resource explaining the hub-and-spoke model, likely from Andrew Lo.
• ADH1 publication in AJHG — Referenced as the publication from Sun-Gou Ji's team on calcium-sensing receptor variants and ADH1 prevalence.
• BridgeBio white paper on rare disease drug development — Mentioned as a white paper discussing the feasibility of rare disease drug development and risk-adjusted NPV.

• BridgeBio - Unlocking Rare Diseases Medicine — Official BridgeBio page describing their approach to rare disease drug development.
• ADH1 publication in AJHG — Peer-reviewed publication supporting the genetic prevalence and penetrance data discussed in the podcast.